Are thiazolidinediones good or bad for the heart?
Type 2 diabetes is a global epidemic contributing to significant cardiovascular morbidity and mortality. The high prevalence of cardiovascular disease can largely be attributed to the metabolic syndrome with its multiple cardiovascular risk factors, including central obesity, hypertension, glucose intolerance, chronic inflammation, and dyslipidemia. The peroxisome proliferator-activated receptor-gamma agonists, the thiazolidinediones, may potentially correct the inflammatory disarray, endothelial dysfunction, dyslipidemia, and plaque vulnerability associated with diabetic cardiovascular disease through their effects on insulin resistance and fat metabolism, yet they can also exacerbate congestive heart failure. This review summarizes basic science, animal, and human data on the effects of thiazolidinediones on cardiovascular disease.
Taylor
Angela M
AM
McNamara
Coleen A
CA
D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D048909:Diabetes Complications / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D006321:Heart / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D024821:Metabolic Syndrome / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D008954:Models, Biological; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology; D047495:PPAR gamma / Q000819:agonists / Q000378:metabolism; D045162:Thiazolidinediones / Q000494:pharmacology / Q000627:therapeutic use*
D047495:PPAR gamma; D045162:Thiazolidinediones